The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

Nefopam Reduces Dysesthesia after Percutaneous Endoscopic Lumbar Discectomy

  • Ok, Young Min (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University) ;
  • Cheon, Ji Hyun (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University) ;
  • Choi, Eun Ji (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University) ;
  • Chang, Eun Jung (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University) ;
  • Lee, Ho Myung (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University) ;
  • Kim, Kyung Hoon (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University)
  • Received : 2015.08.01
  • Accepted : 2015.12.16
  • Published : 2016.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Neuropathic pain, including paresthesia/dysesthesia in the lower extremities, always develops and remains for at least one month, to variable degrees, after percutaneous endoscopic lumbar discectomy (PELD). The recently discovered dual analgesic mechanisms of action, similar to those of antidepressants and anticonvulsants, enable nefopam (NFP) to treat neuropathic pain. This study was performed to determine whether NFP might reduce the neuropathic pain component of postoperative pain. Methods: Eighty patients, who underwent PELD due to herniated nucleus pulposus (HNP) at L4-L5, were randomly divided into two equal groups, one receiving NFP (with a mixture of morphine and ketorolac) and the other normal saline (NS) with the same mixture. The number of bolus infusions and the infused volume for 3 days were compared in both groups. The adverse reactions (ADRs) in both groups were recorded and compared. The neuropathic pain symptom inventory (NPSI) score was compared in both groups on postoperative days 1, 3, 7, 30, 60, and 90. Results: The mean attempted number of bolus infusions, and effective infused bolus volume for 3 days was lower in the NFP group for 3 days. The most commonly reported ADRs were nausea, dizziness, and somnolence, in order of frequency in the NFP group. The median NPSI score, and all 5 median sub-scores in the NFP group, were significantly lower than that of the NS group until postoperative day 30. Conclusions: NFP significantly reduced the neuropathic pain component, including paresthesia/dysesthesia until 1 month after PELD. The common ADRs were nausea, dizziness, somnolence, and ataxia.

Keywords

References

  1. Kim KH. Use of lidocaine patch for percutaneous endoscopic lumbar discectomy. Korean J Pain 2011; 24: 74-80. https://doi.org/10.3344/kjp.2011.24.2.74
  2. Cho JY, Lee SH, Lee HY. Prevention of development of postoperative dysesthesia in transforaminal percutaneous endoscopic lumbar discectomy for intracanalicular lumbar disc herniation: floating retraction technique. Minim Invasive Neurosurg 2011; 54: 214-8. https://doi.org/10.1055/s-0031-1287774
  3. Loeser JD. Pain of neurologic origin in the hips and lower extremities. In: Bonica's management of pain. 3rd ed. Edited by Loeser JD, Bonica JJ. Philadelphia (PA), Lippincott Williams & Wilkins. 2001, pp 1565-78.
  4. Gregori-Puigjane E, Setola V, Hert J, Crews BA, Irwin JJ, Lounkine E, et al. Identifying mechanism-of-action targets for drugs and probes. Proc Natl Acad Sci U S A 2012; 109: 11178-83. https://doi.org/10.1073/pnas.1204524109
  5. Moore RA, Derry S, McQuay HJ, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults. Cochrane Database Syst Rev 2011: CD008659.
  6. Alfonsi P, Adam F, Passard A, Guignard B, Sessler DI, Chauvin M. Nefopam, a nonsedative benzoxazocine analgesic, selectively reduces the shivering threshold in unanesthetized subjects. Anesthesiology 2004; 100: 37-43. https://doi.org/10.1097/00000542-200401000-00010
  7. Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS. Nefopam: a review of its pharmacological properties and therapeutic efficacy. Drugs 1980; 19: 249-67. https://doi.org/10.2165/00003495-198019040-00001
  8. Podranski T, Bouillon TW, Riva T, Kurz AM, Oehmke MJ. Compartmental pharmacokinetics of nefopam during mild hypothermia. Br J Anaesth 2012; 108: 784-91. https://doi.org/10.1093/bja/aer517
  9. Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 2004; 108: 248-57. https://doi.org/10.1016/j.pain.2003.12.024
  10. Czuczwar M, Czuczwar K, Cieszczyk J, Kis J, Saran T, Łuszczki JJ, et al. Nefopam enhances the protective activity of antiepileptics against maximal electroshock-induced convulsions in mice. Pharmacol Rep 2011; 63: 690-6. https://doi.org/10.1016/S1734-1140(11)70580-1
  11. Novelli A, Groppetti A, Rossoni G, Manfredi B, Ferrero-Gutierrez A, Perez-Gomez A, et al. Nefopam is more potent than carbamazepine for neuroprotection against veratridine in vitro and has anticonvulsant properties against both electrical and chemical stimulation. Amino Acids 2007; 32: 323-32. https://doi.org/10.1007/s00726-006-0419-6
  12. Novelli A, Diaz-Trelles R, Groppetti A, Fernandez-Sanchez MT. Nefopam inhibits calcium influx, cGMP formation, and NMDA receptor-dependent neurotoxicity following activation of voltage sensitive calcium channels. Amino Acids 2005; 28: 183-91. https://doi.org/10.1007/s00726-005-0166-0
  13. Verleye M, Andre N, Heulard I, Gillardin JM. Nefopam blocks voltage-sensitive sodium channels and modulates glutamatergic transmission in rodents. Brain Res 2004; 1013: 249-55. https://doi.org/10.1016/j.brainres.2004.04.035
  14. Kim KH, Abdi S. Rediscovery of nefopam for the treatment of neuropathic pain. Korean J Pain 2014; 27: 103-11. https://doi.org/10.3344/kjp.2014.27.2.103
  15. Sittl R, Irnich D, Lang PM. Update on preemptive analgesia: options and limits of preoperative pain therapy. Anaesthesist 2013; 62: 789-96. https://doi.org/10.1007/s00101-013-2225-3
  16. Choi I, Ahn JO, So WS, Lee SJ, Choi IJ, Kim H. Exiting root injury in transforaminal endoscopic discectomy: preoperative image considerations for safety. Eur Spine J 2013; 22: 2481-7. https://doi.org/10.1007/s00586-013-2849-7
  17. Durrieu G, Olivier P, Bagheri H, Montastruc JL; French Network of Pharmacovigilance Centers. Overview of adverse reactions to nefopam: an analysis of the French Pharmacovigilance database. Fundam Clin Pharmacol 2007; 21: 555-8. https://doi.org/10.1111/j.1472-8206.2007.00499.x
  18. Haroutiunian S, Nikolajsen L, Finnerup NB, Jensen TS. The neuropathic component in persistent postsurgical pain: a systematic literature review. Pain 2013; 154: 95-102. https://doi.org/10.1016/j.pain.2012.09.010
  19. Joo YC, Ko ES, Cho JG, Ok YM, Jung GY, Kim KH. Intravenous nefopam reduces postherpetic neuralgia during the titration of oral medications. Korean J Pain 2014; 27: 54-62. https://doi.org/10.3344/kjp.2014.27.1.54

Cited by

  1. Tapentadol: Can It Kill Two Birds with One Stone without Breaking Windows? vol.29, pp.3, 2016, https://doi.org/10.3344/kjp.2016.29.3.153
  2. Earlier treatment improves the chances of complete relief from postherpetic neuralgia vol.30, pp.3, 2017, https://doi.org/10.3344/kjp.2017.30.3.214
  3. Pharmacotherapy for the Prevention of Chronic Pain after Surgery in Adults: An Updated Systematic Review and Meta-analysis vol.135, pp.2, 2016, https://doi.org/10.1097/aln.0000000000003837
  4. A Postoperative Phenomenon of Percutaneous Endoscopic Lumbar Discectomy: Rebound Pain vol.13, pp.8, 2016, https://doi.org/10.1111/os.13088